UNSPSC 51333001: Flucindole

This classification denotes an antipsychotic agent with the molecular formula C14H16F2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5CYU0D0S8M, chemically known as 3-(dimethylamino)-6,8-difluoro-1,2,3,4-tetrahydrocarbazole but generally known as flucindole, which bears US NIH Compound Identifier 38531. European Medicines Agency schedules Flucindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07670MIG.

UNSPSC 51333001 Flucindole is a Commodity code that does not match the scope of the state and local procurement activity recently tagged under it. The three most recent solicitations show no relevant activity in flucindole—a specific pharmaceutical compound. Instead, the opportunities target naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. The code appears to be a misclassification artifact in the source data, and flucindole itself does not reflect what state and local governments are actually buying under this tag.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline appears misdated relative to the posting). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon. Given the misalignment between the code's nominal scope and recent solicitation activity, this code warrants reassessment for coding accuracy or reclassification to better reflect actual state and local pharmaceutical procurement.